Tibet Rhodiola Pharmaceutical Holding Co - Asset Resilience Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has an Asset Resilience Ratio of 15.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tibet Rhodiola Pharmaceutical Holding Co current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 600211 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Tibet Rhodiola Pharmaceutical Holding Co to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥995.32 Million | 15.57% |
| Total Liquid Assets | CN¥995.32 Million | 15.57% |
Asset Resilience Insights
- Good Liquidity Position: Tibet Rhodiola Pharmaceutical Holding Co maintains a healthy 15.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Tibet Rhodiola Pharmaceutical Holding Co Industry Peers by Asset Resilience Ratio
Compare Tibet Rhodiola Pharmaceutical Holding Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Tibet Rhodiola Pharmaceutical Holding Co (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Tibet Rhodiola Pharmaceutical Holding Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.45% | CN¥1.78 Billion ≈ $260.89 Million |
CN¥6.27 Billion ≈ $917.12 Million |
+7.87pp |
| 2024-12-31 | 20.57% | CN¥976.62 Million ≈ $142.91 Million |
CN¥4.75 Billion ≈ $694.68 Million |
+9.34pp |
| 2023-12-31 | 11.23% | CN¥515.34 Million ≈ $75.41 Million |
CN¥4.59 Billion ≈ $671.27 Million |
-8.10pp |
| 2022-12-31 | 19.33% | CN¥792.49 Million ≈ $115.97 Million |
CN¥4.10 Billion ≈ $599.87 Million |
+5.19pp |
| 2021-12-31 | 14.14% | CN¥537.87 Million ≈ $78.71 Million |
CN¥3.80 Billion ≈ $556.45 Million |
+13.64pp |
| 2020-12-31 | 0.51% | CN¥14.96 Million ≈ $2.19 Million |
CN¥2.94 Billion ≈ $430.84 Million |
-2.74pp |
| 2019-12-31 | 3.25% | CN¥90.00 Million ≈ $13.17 Million |
CN¥2.77 Billion ≈ $404.93 Million |
+0.41pp |
| 2016-12-31 | 2.84% | CN¥65.00 Million ≈ $9.51 Million |
CN¥2.29 Billion ≈ $335.20 Million |
+2.80pp |
| 2010-12-31 | 0.04% | CN¥308.80K ≈ $45.19K |
CN¥735.47 Million ≈ $107.62 Million |
-0.05pp |
| 2009-12-31 | 0.10% | CN¥709.60K ≈ $103.84K |
CN¥743.70 Million ≈ $108.83 Million |
+0.08pp |
| 2008-12-31 | 0.01% | CN¥112.40K ≈ $16.45K |
CN¥829.66 Million ≈ $121.41 Million |
-0.03pp |
| 2007-12-31 | 0.04% | CN¥339.80K ≈ $49.72K |
CN¥831.96 Million ≈ $121.74 Million |
+0.01pp |
| 2006-12-31 | 0.03% | CN¥252.00K ≈ $36.88K |
CN¥866.90 Million ≈ $126.86 Million |
+0.02pp |
| 2005-12-31 | 0.01% | CN¥114.60K ≈ $16.77K |
CN¥820.62 Million ≈ $120.08 Million |
-0.46pp |
| 2004-12-31 | 0.48% | CN¥3.69 Million ≈ $540.55K |
CN¥777.25 Million ≈ $113.74 Million |
-0.03pp |
| 2003-12-31 | 0.51% | CN¥3.81 Million ≈ $557.96K |
CN¥754.36 Million ≈ $110.39 Million |
+0.05pp |
| 2002-12-31 | 0.46% | CN¥3.37 Million ≈ $492.55K |
CN¥733.08 Million ≈ $107.27 Million |
-- |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more